A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

被引：5

作者：

Brivio, Erica ^{[1
]}

Lopez-Yurda, Marta ^{[1
,2
,3
]}

Ownes, Cormac ^{[4
]}

Diaz de Heredia, Cristina ^{[5
]}

Bielorai, Bella ^{[6
]}

Rossig, Claudia ^{[7
]}

Van der Velden, Vincent ^{[8
]}

Ammerlaan, Anneke C. J. ^{[1
]}

van der Sluis, Inge M. ^{[1
]}

Den Boer, Monique L. ^{[1
,2
]}

Chen, Ying ^{[9
]}

Sleight, Barbara ^{[10
]}

Brethon, Benoit ^{[11
]}

Nysom, Karsten ^{[12
]}

Stary, Jan ^{[13
]}

Ora, Ingrid ^{[14
]}

Chen-Santel, Christiane ^{[15
]}

Vinti, Luciana ^{[16
]}

Locatelli, Franco ^{[17
]}

Zwaan, Christian Michel ^{[1
,2
]}

机构：

[1] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[2] Erasmus MC, Dept Pediat Oncol Hematol, Sophia Childrens Hosp, Rotterdam, Netherlands

[3] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands

[4] Our Ladys Childrens Hosp Crumlin, Dublin, Ireland

[5] Hosp Univ Vall dHebron Vall dHebron, Pediat Oncol & Hematol Dept, Barcelona, Spain

[6] Sheba Med Ctr, Div Pediat Hematol & Oncol, Ramat Gan, Israel

[7] Univ Childrens Hosp Muenster, Pediat Hematol & Oncol, Munster, Germany

[8] Erasmus MC, Dept Immunol, Rotterdam, Netherlands

[9] Pfizer Inc, Clin Pharmacol, San Diego, CA USA

[10] Pfizer Inc, Groton, CT 06340 USA

[11] Univ Paris, Robert Debre Hosp, AP HP, Dept Pediat Hematol & Immunol, Paris, France

[12] Rigshosp, Copenhagen, Denmark

[13] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic

[14] Karolinska Univ Hosp, Pediat Oncol Unit, Stockholm, Sweden

[15] Charite Univ Med Berlin, Div Hematol & Oncol, Dept Pediat, Berlin, Germany

[16] IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol Oncol Cell & Gene Therapy, Rome, Italy

[17] Univ Rome Sapienza, Dept Hematol Oncol & transfus Med, Osped Pediat Bambino Gesu, Rome, Italy

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122411

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2629

引用

页数：5

共 50 条

[21] A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage
Advani, Anjali S.
Stein, Anthony S.
Kantarjian, Hagop M.
Shustov, Andrei R.
DeAngelo, Daniel J.
Ananthakrishnan, Revathi
Liau, Katherine
Vandendries, Erik
Stock, Wendy
BLOOD, 2014, 124 (21)
[22] Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia
Calvo, Charlotte
Cabannes-Hamy, Aurelie
Adjaoud, Dalila
Bruno, Benedicte
Blanc, Laurence
Boissel, Nicolas
Tabone, Marie-Dominique
Willson-Plat, Genevieve
Villemonteix, Juliette
Baruchel, Andre
Brethon, Benoit
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (01) : E53 - +
[23] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Kantarjian, Hagop
Thomas, Deborah
Jorgensen, Jeffrey
Kebriaei, Partow
Jabbour, Elias
Rytting, Michael
York, Sergernne
Ravandi, Farhad
Garris, Rebecca
Kwari, Monica
Faderl, Stefan
Cortes, Jorge
Champlin, Richard
O'Brien, Susan
CANCER, 2013, 119 (15) : 2728 - 2736
[24] A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Brivio, Erica
Hoogendijk, Raoull
Chantrain, Christophe
Rialland, Fanny
Contet, Audrey
Elitzur, Sarah
Dalla-Pozza, Luciano
Kallay, Krisztian
Li, Chi Kong
Kato, Motohiro
Markova, Inna V.
Schmiegelow, Kjeld
Bodmer, Nicole
Pieters, Rob
Zwaan, Christian Michel
BLOOD, 2019, 134
[25] A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas
Pirosa, Maria C.
Zhang, Lu
Hitz, Felicitas
Novak, Urban
Hess, Dagmar
Terrot, Tatiana
Pascale, Mariarosa
Mazzucchelli, Luca
Bertoni, Francesco
Cavalli, Franco
Zucca, Emanuele
Stathis, Anastasios
LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 117 - 123
[26] Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia
Buckwalter, M
Dowell, JA
Korth-Bradley, J
Gorovits, B
Mayer, PR
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 873 - 880
[27] The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study
Ozcan, Muhit
Cassaday, Ryan D.
Singh, Pawan
Zarzycka, Ewa
Zhang, Xin
Negre, Eric
Vandendries, Erik
Altuntas, Fevzi
BLOOD, 2021, 138
[28] Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial
Pennesi, Edoardo
Brivio, Erica
Ammerlaan, Anneke C. J.
Jiang, Yilin
van der Velden, Vincent H. J.
Beverloo, Berna
Sleight, Barbara
Rives, Susana
de Heredia Rubio, Cristina Diaz
Sirvent, Francisco J. Bautista
Rubio-San-Simon, Alba
Rialland, Fanny
Rizzari, Carmelo
Bielorai, Bella
Petit, Arnaud
Bruno, Benedicte
Ora, Ingrid
Nilsson, Anna
Engstler, Gernot
Rossig, Claudia
Brethon, Benoit
Locatelli, Franco
Zwaan, Christian M.
BLOOD, 2022, 140 : 8976 - 8978
[29] Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Jain, Nitin
Maiti, Abhishek
Ravandi, Farhad
Konopleva, Marina
Daver, Naval
Kadia, Tapan
Pemmaraju, Naveen
Short, Nicholas
Kebriaei, Partow
Ning, Jing
Cortes, Jorge
Jabbour, Elias
Kantarjian, Hagop
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : 1000 - 1007
[30] INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Papayannidis, Cristina
Petracci, Elisabetta
Zappasodi, Patrizia
Fracchiolla, Nicola
Ciceri, Fabio
Sartor, Chiara
Roncoroni, Elisa
Di Raimondo, Francesco
Mattei, Daniele
Giannini, Maria Benedetta
Lanza, Francesco
Gottardi, Michele
Del Principe, Maria Ilaria
Borlenghi, Erika
Fumagalli, Monica
Vallisa, Daniele
Sica, Simona
Di Renzo, Nicola
Fabbiano, Francesco
Todisco, Elisabetta
de Fabritiis, Paolo
Luppi, Mario
Passamonti, Francesco
Corradini, Paolo
Petruzziello, Fara
Pane, Fabrizio
Ferrara, Felicetto
Mambelli, Greta
Volpi, Roberta
Frabetti, Federica
Zingaretti, Chiara
Marconi, Giovanni
Martinelli, Giovanni
CANCER, 2025, 131 (07)

← 1 2 3 4 5 →